公开(公告)号：US20170296838A1

公开(公告)日：2017-10-19

申请号：US15517272

申请日：2015-08-31

申请人： Teijin Pharma Limited

发明人： Atsushi ASAHINA ,  Kenji TOJO ,  Rei TAMIYA

IPC分类号： A61N2/00 ,  A61N2/02 ,  A61N1/00

CPC分类号： A61N2/006 ,  A61B90/30 ,  A61B2090/363 ,  A61B2090/3937 ,  A61G13/121 ,  A61G15/125 ,  A61G2210/50 ,  A61N1/00 ,  A61N2/00 ,  A61N2/02

摘要： The purpose of the invention is to provide a transcranial magnetic stimulation system capable of guiding a patient into an optimum posture for treatment. The system 1 of the invention includes an optical device 502 for projecting a light spot 805 to a head of a patient and detecting a reflection light of the light spot; a memory means 71 for memorizing information included in the reflection light detected by the optical device as a reference information when the projected light spot on the patient overlaps a marking (800) provided on the patient; a calculation means 72 for using the reference information memorized in the memory means and a comparison information included in the reflection light of the light spot to calculate an overlap ratio between the marking and the light spot corresponding to the comparison information; and a display means 504 for displaying the overlap ratio.

公开(公告)号：US20170291037A1

公开(公告)日：2017-10-12

申请号：US15516975

申请日：2015-08-31

申请人： TEIJIN PHARMA LIMITED

发明人： Rei TAMIYA ,  Hideharu SHIMURA ,  Jun MATSUI

IPC分类号： A61N2/00 ,  A61N2/02

CPC分类号： A61N2/006 ,  A61N1/0526 ,  A61N1/0529 ,  A61N2/00 ,  A61N2/02

摘要： The purpose of the invention is to provide a transcranial magnetic stimulation system capable of being readily set into an optimum position for treatment. The system 1 of the invention includes a support mechanism 30 configured to support a patient, a first mechanism 200 configured to move the coil in a left and right direction of the patient about a first axis 220 extending in a back and forth direction of the patient relative to a head of patient supported by the support mechanism, and a second mechanism 300 configured to move the coil in the back and forth direction about a second axis 320 extending in the left and right direction relative to the head of the patient.

公开(公告)号：US20170274171A1

公开(公告)日：2017-09-28

申请号：US15508564

申请日：2015-09-17

申请人： Teijin Pharma Limited

发明人： Maki HOJO ,  Katsushi FUJIMOTO

IPC分类号： A61M16/10 ,  C01B13/02 ,  B01J20/34 ,  A61M16/20 ,  B01D53/047

CPC分类号： A61M16/101 ,  A61M16/203 ,  A61M2202/0208 ,  A61M2205/3341 ,  B01D53/0423 ,  B01D53/0446 ,  B01D53/047 ,  B01D2256/12 ,  B01D2257/102 ,  B01D2259/40028 ,  B01D2259/40035 ,  B01D2259/4533 ,  B01J20/3491 ,  C01B13/0259 ,  C01B13/027 ,  A61M2202/0007

摘要： Provided is an oxygen concentration device which, as an oxygen concentration device having a reduced difference in flow rates of gas which flows through a pressure equalization valve of a pressure equalization path during a purge step and a pressure equalization step, is provided at at least one end side of the pressure equalization valve with a pressure control member having a difference in pressure loss due to the direction of gas flow so that pressure loss of the gas which flows through the pressure equalization path in one direction becomes nearly equal to that of the gas which flows therethrough in the opposite direction.

公开(公告)号：US09682046B2

公开(公告)日：2017-06-20

申请号：US14349512

申请日：2012-10-05

申请人： TEIJIN PHARMA LIMITED

发明人： Yasumi Nishiwaki ,  Takashi Murakami ,  Nobuaki Eto ,  Keiichiro Imaizumi ,  Akihito Ohtaki ,  Kenji Shimazaki

IPC分类号： A61K33/44 ,  C01B31/08 ,  A61K9/70 ,  C01B31/10 ,  B01J20/20 ,  B01J20/28 ,  A61K31/01 ,  D01F9/14

CPC分类号： A61K9/70 ,  A61K33/44 ,  B01J20/20 ,  B01J20/28004 ,  B01J20/28023 ,  B01J20/28066 ,  B01J20/28069 ,  B01J20/2808 ,  C01B32/336 ,  D01F9/14

摘要： The present invention aims to provide an adsorbent for oral administration comprising ACF that has high adsorption or removal performance by adsorbing or removing toxic substances in the living body greatly and rapidly. The present invention is an adsorbent for oral administration comprising activated carbon fibers for treating or preventing kidney diseases or dialysis complications.

公开(公告)号：US09637469B2

公开(公告)日：2017-05-02

申请号：US14441074

申请日：2013-11-13

申请人： Teijin Pharma Limited

发明人： Akinobu Maruyama ,  Hirofumi Kamada ,  Mika Fujinuma ,  Susumu Takeuchi ,  Hiroshi Saitoh ,  Yoshimasa Takahashi

IPC分类号： C07D401/04 ,  C07D409/14 ,  A61K31/4439 ,  C07D401/12 ,  C07D491/048

CPC分类号： C07D409/14 ,  A61K31/4439 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D491/048 ,  A61K2300/00

摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

公开(公告)号：US09078807B2

公开(公告)日：2015-07-14

申请号：US12527084

申请日：2008-02-15

申请人： Masahiko Narasaki ,  Tomoya Akutagawa ,  Takamasa Maki ,  Minoru Uemura

发明人： Masahiko Narasaki ,  Tomoya Akutagawa ,  Takamasa Maki ,  Minoru Uemura

IPC分类号： B29C43/06 ,  A61J3/10 ,  B30B7/04 ,  B30B11/02 ,  B30B15/06

CPC分类号： A61J3/10 ,  B30B7/04 ,  B30B11/027 ,  B30B15/065

摘要： A tablet compression machine which can manufacture a tablet having a plurality of layers by applying secondary compression molding to a columnar primary compression molded product formed by a plurality of layers and whose two bottom faces may be bulged, comprising at least a mortar, an upper pestle, and a lower pestle, in which the mortar is substantially in a shape in which a part of a flat plate is punched by a closed curve in a direction perpendicular to a plane of the flat plate, the upper and lower pestles are in a shape fitted with an inner face of the mortar, a space formed by an inner face of the mortar, a lower face of the upper pestle, and an upper face of the lower pestle is in a shape of an intended tablet in the secondary compression molding, a dent formed by the inner face of the mortar and the upper face of the lower pestle can constitute a shape suitable for receiving the primary compression molded product, and a direction of the secondary compression molding is different from the compression molding direction of the primary compression molded product. According to such a tablet compression machine, a multilayer tablet in a shape having a multilayer structure and not limited to columnar can be manufactured.

摘要翻译： 一种片式压缩机，其可以通过对由多层形成并且其两个底面可以隆起的柱状初级压缩成型品进行二次压缩成型制造具有多层的片剂，所述片状压片机的两个底面可以隆起，至少包括研钵，上杵 ，以及下杵，其中，所述砂浆基本上为平板的一部分在与所述平板的平面垂直的方向上由闭合曲线冲压的形状，所述上下杵为形状 装配有砂浆的内表面，由研钵的内表面形成的空间，上杵的下表面和下杵的上表面在二次压缩成型中为预期的片剂的形状， 由砂浆的内表面和下杵的上表面形成的凹陷可以构成适于接收初级压缩成型品的形状，二次压缩成型的方向不同 从初级压缩成型品的压缩成型方向。 根据这样的片压缩机，可以制造具有多层结构但不限于柱状的形状的多层片剂。

公开(公告)号：US20150151020A1

公开(公告)日：2015-06-04

申请号：US14399117

申请日：2013-05-13

申请人： TEIJIN LIMITED ,  TEIJIN PHARMA LIMITED ,  THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

发明人： Yukako Kageyama ,  Kentaro Fujinaga ,  Ayuko Yamaguchi ,  Yusuke Akiyama ,  Akitoshi Oono ,  Susumu Honda ,  Makoto Satake ,  Hiroaki Kaneko ,  Takayuki Imamura ,  Ryoichi Kawamura ,  Masaki Hirashima

IPC分类号： A61L26/00 ,  A61L24/00 ,  A61L24/04

摘要： A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.

摘要翻译： 包含选自纤维蛋白原和凝血酶中的至少一种蛋白质的聚合物组合物和至少一种选自脂族聚酯和水溶性聚合物的聚合物的聚合物组合物的片状产物和包含 提供由纤维蛋白原和水溶性聚合物组成的第一聚合物组合物层和由凝血酶和脂族聚酯组成的第二聚合物组合物层。 这些形成的产品被施加到伤口部位并用作止血材料。

公开(公告)号：US20150132279A1

公开(公告)日：2015-05-14

申请号：US14400978

申请日：2013-05-13

申请人： TEIJIN LIMITED ,  TEIJIN PHARMA LIMITED ,  THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

发明人： Yukako Kageyama ,  Kentaro Fujinaga ,  Ayuko Yamaguchi ,  Yusuke Akiyama ,  Souichirou Katou ,  Yukiko Kimura ,  Susumu Honda ,  Makoto Satake ,  Hiroaki Kaneko ,  Ayumi Ishiwari ,  Masaki Hirashima

IPC分类号： A61K47/38 ,  A61K38/47 ,  A61K38/46 ,  A61K38/17 ,  A61K38/48

CPC分类号： A61K47/38 ,  A61K9/7007 ,  A61K38/1709 ,  A61K38/465 ,  A61K38/47 ,  A61K38/4833 ,  A61L15/225 ,  A61L17/10 ,  A61L27/26 ,  A61L27/505 ,  A61L28/0026 ,  A61L29/049 ,  A61L31/041 ,  A61L31/143 ,  C12Y302/01021 ,  C08L1/00 ,  C08L89/00

摘要： A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.

摘要翻译： 一种蛋白质组合物，其包含甘氨酸，苯丙氨酸和组氨酸和/或纤维素醚衍生物作为添加剂的混合物，并具有耐辐射灭菌功能。

公开(公告)号：US08968779B2

公开(公告)日：2015-03-03

申请号：US13704345

申请日：2011-06-15

申请人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

发明人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

IPC分类号： A61K9/24 ,  A61K9/28 ,  A61K31/426 ,  A61K9/20

CPC分类号： A61K9/2866 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/426

摘要： Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.

摘要翻译： 公开了一种控制释放有核的片剂，其由内核和覆盖内核的外层组成，并且能够维持2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸 血液中的酸长时间达到一定值或更高。 控释片的特征在于内核含有2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸，外层含有2-（3-氰基-4-异丁氧基苯基） - 4-甲基-5-噻唑甲酸和相对于外层重量为16（w / w）％以上的凝胶形成性水溶性聚合物。

公开(公告)号：US08946440B2

公开(公告)日：2015-02-03

申请号：US12989838

申请日：2009-04-27

申请人： Yasumichi Fukuda ,  Yoshikazu Asahina ,  Masanori Takadoi ,  Masanori Yamamoto

发明人： Yasumichi Fukuda ,  Yoshikazu Asahina ,  Masanori Takadoi ,  Masanori Yamamoto

IPC分类号： A61K31/381 ,  C07D277/34 ,  C07F9/6509 ,  C07D213/75 ,  C07D231/38 ,  C07D241/20 ,  C07D261/14 ,  C07D277/20 ,  C07D277/44 ,  C07D277/82 ,  C07D285/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D417/04 ,  C07D417/12 ,  C07D513/04 ,  C07F9/54 ,  C07F9/6539

CPC分类号： C07C309/77 ,  C07C2601/02 ,  C07C2601/08 ,  C07D213/75 ,  C07D231/38 ,  C07D241/20 ,  C07D261/14 ,  C07D277/20 ,  C07D277/44 ,  C07D277/82 ,  C07D285/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D417/04 ,  C07D417/12 ,  C07D513/04 ,  C07F9/5442 ,  C07F9/650952 ,  C07F9/6539

摘要： A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).

摘要翻译： 提供具有降血糖作用的化合物。 该化合物及其药学上可接受的盐可用于治疗或预防糖尿病，肥胖症等。 该化合物由通式（1）表示：（其中R 1和R 2各自独立地为氢原子，卤素原子，氨基，羟基，羟基氨基，硝基，氰基，氨磺酰基 C1〜C6烷基，C1〜C6烷氧基，C1〜C6烷基硫烷基，C1〜C6烷基亚磺酰基，C1〜C6烷基磺酰基或C1〜C6烷氧基-C1〜C6烷基磺酰基， A是取代或未取代的杂芳基）。